← board
GCAN
distress 6/10 · elevated risk$0.31-8%today-31% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
-100%
Price & events
+342.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-7.5%
1D
+22.8%
1W
+109.5%
1M
+84.7%
3M
+342.9%
6M
+3.3%
1Y
-70.5%
2Y
-96.3%
5Y
-93.2%
All
Overview
- Market Cap
- $292.93K
- Volume
- 350
- 52 Week Range
- $0.05 – $0.45
- Total Shares
- 944.93K
- Float Shares
- 878.26K
- % Held by Insiders
- 53.10%
- % Held by Institutions
- 0.00%
- RVOL
- 0.08x
- Beta
- 0.37
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.